Short congress report from AACR.NCI.EORTC Scientific meeting:
Molecular Targets and Cancer Therapeutics in cancer, November 5-9, 2015 in Boston, USA with comments from CEO Nils Brünner.
Just returned from AACR.NCI.EORTC Scientific meeting: Molecular Targets and Cancer Therapeutics in cancer, we can summarize the meeting as follows:
The meeting, which was hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, gathered approximately 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe. At the meeting new anti-cancer targets and drug mechanisms of action were presented. Hence, this was an excellent opportunity for WntResearch to present interim data from the Foxy-5 clinical phase 1 study.
WntResearch had the privilege to present an abstract (poster presentation) of the first preliminary results from the Foxy-5 clinical phase 1 study. The poster session was very busy with many visitors from the Pharma Industry. As we are aware, several Pharma Companies are currently interested in different Wnt-pathways and several of them have also ongoing programs with inhibition of several of the Wnt proteins. Many of these companies were present at the meeting and visited our presentation. We had several in depths discussions on whether the Wnt-5a pathway should be inhibited or stimulated. The discussions confirmed our current view on how to utilize the Wnt-5a pathway in the development anti-metastatic therapy. All available data in breast cancer, colorectal cancer and prostate cancer, indicate that the correct approach should be to mimic Wnt-5a in cancer patients with low levels of this protein in their cancer cells.
From this perspective we are happy that WntResearch is the only Company with access to a specific Wnt-5a agonist (Foxy-5). Other Pharma Companies have much less specific drugs that target many of the different Wnt-molecules/frizzle receptors. Or as one visitor framed it: “WntResearch has a clean approach, while others are dealing with “dirty” drugs”.
We got a lot of positive comments on our phase 1 clinical data with Foxy-5 and also some good suggestions for how to evaluate our data when we make the final report. Finally, we made some great contacts and several of the Pharma Companies wanted to follow-up with us.
CEO Nils Brünner, 2015-11-10